CD79A and ovarian cancer: Notably, recent studies in a large cohort of patients with ovarian cancer revealed that polyclonal IgA antibodies derived from TABs bind to IgA receptors on tumor cells, triggering pIgR-mediated IgA transcytosis and impeding tumor growth, ultimately enhancing tumor cell killing by T cells (106).